Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study

被引：0
作者：
Liu, Yin
Zuo, Wen-Jia
Wang, Ruo-Xi
Wang, Zhong-Hua
Shao, Zhi-Ming
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
基金：
上海市自然科学基金;
关键词：
D O I：
10.1158/1538-7445.SABCS22-P1-11-20
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-20
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [32] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08) : 724 - 734
  • [33] Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study
    Zhou, Meirong
    Wang, Shouman
    Wan, Nengbin
    Yuan, Songlin
    Hu, Xiongqiang
    Zhou, Wei
    Qing, Bohua
    Liu, Mingwen
    Sun, Weihua
    Fan, Peizhi
    Wang, Jianguo
    Cao, Hong
    Xu, Haifan
    Dai, Bin
    Tang, Peizhi
    Qian, Liyuan
    Zhao, Xi
    Xiao, Jun
    Zhou, Huaiying
    Hu, Jinhui
    Ding, Li
    Tripodi, Domenico
    Zdenkowski, Nicholas
    O'Keefe, Thomas J.
    Sanchez, Alejandro Martin
    Chen, Li
    Zhang, Ping
    Xu, Feng
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (24)
  • [34] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
  • [35] Real-world clinical study of trastuzumab biosimilar (Zercepac) and pertuzumab (Perjeta) in combination with chemotherapy for neoadjuvant treatment of HER-2-positive breast cancer
    Bao, Yu-Fei
    Yang, Jin-Zhe
    Li, Xiu-Feng
    Zhu, Jing-Jun
    ASIAN JOURNAL OF SURGERY, 2024, 47 (07) : 3225 - 3228
  • [36] Dual anti-HER2 Therapy with Pertuzumab and Trastuzumab versus Trastuzumab Alone in Addition to Anthracycline and Taxane-Based Neoadjuvant Therapy in Patients with HER2-Positive Early-Stage Breast Cancer; Real-World Data
    Sharaf, Baha'
    Tamimi, Faris
    Salama, Osama
    Zayed, Anas
    El Khatib, Osama
    Khater, Suhaib
    Horani, Malek
    Al-Sawajneh, Suhaib
    AL-Masri, Yosra
    Abdel-Razeq, Hikmat
    CANCER RESEARCH, 2024, 84 (09)
  • [37] Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
    Yamashita-Kashima, Yoriko
    Shu, Sei
    Yorozu, Keigo
    Moriya, Yoichiro
    Harada, Naoki
    ONCOLOGY LETTERS, 2017, 14 (04) : 4197 - 4205
  • [38] Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2014, 12 (03) : 84 - 86
  • [39] Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer
    Irelli, Azzurra
    Ceriello, Laura
    Patruno, Leonardo Valerio
    Tessitore, Alessandra
    Alesse, Edoardo
    Cannita, Katia
    Fabiani, Donatello
    BIOMEDICINES, 2024, 12 (01)
  • [40] A Multicentre Study of Pathological Complete Response in HER2-positive Early Breast Cancer Treated with Neoadjuvant Pertuzumab and Trastuzumab
    Chambers, J.
    Maxwell, A.
    Kingdon, S.
    CLINICAL ONCOLOGY, 2019, 31 (07) : E106 - E106
12345